Investment record achieved in the first half in Catalonia: €342 M by June 2025
The BioRegion of Catalonia has reached a record level of investment in health startups and scaleups during the first half of 2025, with a total of €342 million, according to provisional data from Biocat. This figure surpasses all historical records for a half-year period and comes in a context of clear recovery in investment activity, marked by a strong presence of international venture capital and a notable rebound in competitive grants.
The biotechnology sector is leading the growth, with €227 million raised in just six months. This figure already surpasses the previous all-time high, reached in 2022 with €220 M, and consolidates the strategic role of biotech companies in the BioRegion’s innovation landscape.
Competitive grants have also performed strongly: €59.8 million have been awarded, very close to the all-time high of €61.3 M recorded in 2023. A significant portion of these funds comes from the CDTI, which continues to play a key role in public funding for business R&D.
The top 5 rounds of the semester
- SpliceBio (112 M€ – Series B)
Biotech company specialised in gene therapies. This is the largest funding round ever recorded in the BioRegion, led by EQT Life Sciences and Sanofi Ventures, two international funds. NEA, Ysios Capital, Novartis Venture Fund, Roche Venture Fund, and UCB Ventures also participated. The funds will be used to advance its pipeline of ophthalmic therapies towards the clinic.
- DeepUll (€50 M – Series C)
Diagnostic startup specialised in sepsis and antimicrobial resistance. The round was led by Columbus Venture Partners, Panakès Partners and Mérieux Equity Partners. Other participants included Aliath Bioventures, We Venture Capital, CG Health Ventures, GESAMO, Innvierte-CDTI, Asabys Partners and the Official Credit Institute (ICO). The funds will be used for clinical validation and regulatory approval of its sepsis diagnostic test.
- Seqera Labs (€26 M – Series B)
Specialised in bioinformatics computing infrastructure. The round was led by Addition, an international fund based in the United States, with participation from BoxOne Ventures, Speedinvest, Talis Capital, SNR, and Amino Collective. The funds will drive global expansion and the development of its scientific workflow environment.
- Aortyx (€9,6 M – Series A)
Medtech company developing endovascular devices to treat aortic dissections. The round was closed with Clave Capital and Ship2B Ventures as lead investors, supported by Nara Capital, CDTI and the European Commission. The investment is aimed at launching clinical studies and industrialising its medical solution.
- Biorce (€5 M – International Round)
AI platform applied to drug discovery. The round was led by Norrsken VC, an impact fund from Sweden making its first investment in the BioRegion. This investment reinforces the growing trend of attracting international capital for AI-based health projects.
Quarterly investment evolution (2021–2025)
The following chart shows the quarterly evolution of investment raised over the past 5 years, including the different types of funding.
The second quarter of 2025 recorded the highest quarterly investment figure ever in the BioRegion, with over €300 M in deals.
With these figures, Catalonia consolidates its position as a leading hub for investment in health innovation, combining international investment, sectoral diversification (biotech, digital health, medtech), and support from public instruments such as the CDTI, which continues to strengthen the business R&D ecosystem.
